Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tvardi Therapeutics Inc (TVRD)

Tvardi Therapeutics Inc (TVRD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,898
  • Shares Outstanding, K 9,381
  • Annual Sales, $ 7,140 K
  • Annual Income, $ -70,870 K
  • EBIT $ -23 M
  • EBITDA $ -22 M
  • 60-Month Beta 0.14
  • Price/Sales 5.30
  • Price/Cash Flow N/A
  • Price/Book 1.19

Options Overview Details

View History
  • Implied Volatility 309.44% (-12.29%)
  • Historical Volatility 61.64%
  • IV Percentile 67%
  • IV Rank 45.61%
  • IV High 557.56% on 01/16/26
  • IV Low 101.35% on 11/21/25
  • Expected Move (DTE 11) 4.42 (115.71%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 39
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 663
  • Open Int (30-Day) 751
  • Expected Range 0.00 to 8.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.55
  • Number of Estimates 3
  • High Estimate -0.49
  • Low Estimate -0.58
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.50 +9.14%
on 02/06/26
4.89 -21.88%
on 01/22/26
-0.73 (-16.04%)
since 01/09/26
3-Month
3.50 +9.14%
on 02/06/26
4.89 -21.88%
on 01/22/26
-0.20 (-4.98%)
since 11/07/25
52-Week
3.50 +9.14%
on 02/06/26
43.65 -91.25%
on 10/10/25
-11.18 (-74.53%)
since 02/07/25

Most Recent Stories

More News
Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule...

TVRD : 3.82 (+2.69%)
Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights

Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the placebo group Topline healthy volunteer data from...

TVRD : 3.82 (+2.69%)
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options

TVRD : 3.82 (+2.69%)
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss...

TVRD : 3.82 (+2.69%)
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options

TVRD : 3.82 (+2.69%)
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options

TVRD : 3.82 (+2.69%)
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options

TVRD : 3.82 (+2.69%)
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options

TVRD : 3.82 (+2.69%)
Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven...

TVRD : 3.82 (+2.69%)
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tvardi To Contact Him Directly To Discuss Their Options

TVRD : 3.82 (+2.69%)

Business Summary

Tvardi Therapeutics Inc. is a privately held, clinical-stage, biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Tvardi Therapeutics Inc., formerly known as Cara Therapeutics Inc.,...

See More

Key Turning Points

3rd Resistance Point 4.20
2nd Resistance Point 4.03
1st Resistance Point 3.92
Last Price 3.82
1st Support Level 3.64
2nd Support Level 3.47
3rd Support Level 3.36

See More

52-Week High 43.65
Fibonacci 61.8% 28.31
Fibonacci 50% 23.58
Fibonacci 38.2% 18.84
Last Price 3.82
52-Week Low 3.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar